286
Participants
Start Date
July 10, 2025
Primary Completion Date
July 9, 2027
Study Completion Date
November 30, 2028
Sintilimab
concurrent sintilimab 200mg q3w for 2 cycles followed by maintenance sintilimab 200mg q3w for 15 cycles (approximately 1 year total treatment duration) until disease progression or unacceptable toxicity
radiotherapy
The experimental group will initiate radiotherapy within 4 months postoperatively with prescribed doses of 44-50Gy in 22-25 fractions to the tumor bed and 56-60Gy in 22-25 fractions to narrow-margin areas adjacent to major blood vessels
TACE
The control group will receive the first TACE procedure within 4 months postoperatively, with the decision on administering a second TACE to be determined by the investigator based on the patient's condition and first TACE response assessment.
RECRUITING
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
Peking University People's Hospital
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Beijing 302 Hospital
OTHER
Beijing Ditan Hospital
OTHER
The Third Affiliated Hospital of Naval Medical University
UNKNOWN
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER